Crystalline acetylcholinesterase inhibitor forms A, B, C for neurodegenerative diseases

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted Patent US12590061B2 to Shanghai Institute of Materia Medica, Chinese Academy of Sciences covering crystalline forms A, B, and C of an acetylcholinesterase inhibitor compound (2-((1-(2-fluorobenzyl)-4-fluoropiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-1-indanone). The patent, filed November 24, 2020 as Application No. 17780449 with 10 claims, protects the stable, low-hygroscopicity crystalline forms used for preventing and treating neurodegenerative diseases.

View original document View source feed page

What changed

The USPTO issued Patent US12590061B2 granting exclusive rights to Shanghai Institute of Materia Medica for three crystalline forms (A, B, C) of an acetylcholinesterase inhibitor compound. The patent protects the preparation method and pharmaceutical applications of these forms, which demonstrate high stability, low hygroscopicity, and absence of water or solvent. The compound targets neurodegenerative diseases through acetylcholinesterase inhibition.

Pharmaceutical companies and researchers developing similar acetylcholinesterase inhibitors should review this patent to assess freedom-to-operate implications for their drug development programs. Parties interested in licensing or challenging this patent should consult the full USPTO record and claims. No immediate compliance actions or deadlines are associated with this patent grant.

Source document (simplified)

← USPTO Patent Grants

Crystalline form of acetylcholinesterase inhibitor and preparation method therefor and application thereof

Grant US12590061B2 Kind: B2 Mar 31, 2026

Assignee

SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventors

Hong Liu, Yu Zhou, Haiyan Zhang, Yan Fu, Jian Li, Hualiang Jiang, Xican Tang, Kaixian Chen

Abstract

The present invention provides a crystalline form of an acetylcholinesterase inhibitor, a preparation method therefor and application thereof. Specifically, the crystalline form is crystalline form A, crystalline form B and crystalline form C of 2-((1-(2-fluorobenzyl)-4-fluoropiperidin-4-yl) methylene)-5, 6-dimethoxy-2, 3-dihydro-1-indanone. The crystalline form of the present invention does not contain water and solvent, has high stability and low hygroscopicity, is easy to process, and is very suitable for preparing drugs for preventing and/or treating neurodegenerative diseases.